Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6146623

Title:In vitro-derived genetically altered human neutrophil precursor cells and methods for administering the same
Inventors:Bender, James G.; Lindenhurst, IL, USA
Maples, Phillip B.; Waukegan, IL, USA
Smith, Stephen; Arlington Heights, IL, USA
Unverzagt, Kristen L.; Palatine, IL, USA
Van Epps, Dennis E.; Cary, IL, USA
Summary:Described herein are compositions containing human neutrophil precursor cells with a high content of myeloblasts and pro-myelocytes, methods and uses thereof. The invention relates to genetically altered human neutrophil precursor cells with a cellular component containing approximately 16% human myeloblasts and promyelocytes which have been derived from neutrophil progenitor cells obtained from peripheral blood, bone marrow or cord blood, and less than approximately 5% colony forming units (CFU) of at least 50 cells. Multiple embodiments of the invention are provided. Therapeutic applications in the treatment of genetic or acquired neutropenia are included.
Abstract:A composition comprising genetically altered human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% human myeloblasts and promyelocytes, which have been derived from neutrophil progenitor cells obtained from peripheral blood, bone marrow or cord blood, and less than about 5% colony forming units (CFU) of at least about 50 cells is provided. An alternative composition comprising genetically altered human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% CD15+CD11b- cells and less than about 5% colony forming units (CFU) of at least about 50 cells also is provided, wherein at least about 60% of the CD15+CD11b- cells are myeloblasts and promyelocytes.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6146623
Application Number:US1995000485579
Date Filed:07/06/1995
Date Published:14/11/2000
Assignee:Nexell Therapeutics Inc., Irvine, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021